465 results about "Immune complex deposition" patented technology

The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and / or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and / or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and / or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and / or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The invention discloses a milk allergen test plate, which belongs to the gold immunochromatography detection. According to the milk allergen test plate disclosed by the invention, two ends of a PVC (polrvinyl chloride) base plate are respectively provided with a to-be-tested sample zone and an absorption zone. Colloidal gold mark antigens prepared by respectively marking colloidal gold into casein, beta lactoglobulin and alpha lactalbumin and mixing are orderly arranged between the sample zone to be tested and the absorption zone, and a nitrocellulose membrane is respectively provided with a detection zone coated with mixed milk allergen and a quality control zone coated with anti-beta lactoglobulin antibodies. In detection, color lines are formed in the detection zone and the quality contol zone when an immune complex is formed by specific milk antibodies contained in samples. If the samples do not contain specific milk antibodies, the detection zone does not display color, and only one color line is formed in the quality control zone. The milk allergen test plate disclosed by the invention with the design has the advantages of strong pertinence to the allergen detection, simplicity in operation, low cost and high sensitivity and the like, and can prevent the phenomenon of missed diagnosis in the single antibody detection. The milk allergen test plate is applied for rapidly screening patient allergic to milk, and is especially suitable for being used by primary medical treatment units.

The invention is based in part on the finding that suppressing regulatory T cell function is needed in order to convert passive immunity into active antigen-specific immunity. Generally, the methods of the invention comprise at least the combination of: (1) increasing the amount of immune complexes in the subject, wherein the immune complex comprises a target antigen and a immunoglobulin molecule comprising (i) a variable region specific to the target antigen and (ii) a Fc receptor binding region; and (2) inhibiting regulatory T cell function or decreasing / depleting the regulatory T cell population in the subject.

The present invention discloses a quantum point labeled sandwich immunodetection method and its diagnosis kit. It is a new type sandwich immunodetection method using QDs nano particle as label to make antigen antibody specificity sandwich reaction. It includes the following processes: firstly, directly or indirectly enveloping captured antibody in microwell of polystyrene plate, forming captured antibody-antigen-detection antibody three-layer sandwich luminescent immune complex and fluorescence intensity detection. According to that every QD has narrow and symmetrical fluorescence spectral peak it can select and use quantum point label needle sending different light to simultaneously detect several antigens to be tested in same sample.

A method is disclosed for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an illustrative embodiment of the invention, the analyte is a drug, such as marijuana, cocaine, methamphetamine, methyltestosterone, or mesterolone. The method involves attaching antigens to the surface of a solid support in a preselected pattern to form an array wherein the locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to antigens in the array, thereby forming immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, thereby forming an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, can be coupled to a test for identity such that the results of the assay can be positively correlated to the subject's identity.

The invention discloses a new traditional Chinese medicine composition for treating chronic hepatitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following Chinese medicinal herbs of dried orange peel, rhizoma cyperi, pericarpium citri reticulatae viride, radix scrophulariae, root of rehmannia, folium isatidis, root of kudzu vine, houttuynia cordata, indigo naturalis, peach kernel, red flower, radix paeoniae alba, Tuckahoe, rhizoma alismatis, oriental wormwood, desmodium, polygonum cuspidatum, root of red-rooted salvia, radix bupleuri, angelica sinensis, herba lycopi, earthworm, goldthread, felwort and root bark of the peony tree. The traditional Chinese medicine composition can be prepared into a common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve the symptoms of mild acratia, inappetence, abdominal distension, pain over the liver and the like of chronic persisting hepatitis, and can improve the symptoms of asthenia, poor appetite, abdominal distension, semiliquid, pain over the liver, poor complexion, poorer health, manpower reduction, hepatomegaly accompanied with haphalgesia and rap pain, and splenomegaly of the chronic active hepatitis and the symptoms of jaundice, spider angioma, liver palms, acne and the like caused by the chronic hepatitis. The invention can also improve the symptoms of long-term obvious dysfunction of liver, ALT continuous increase or repeated fluctuation, albumin reduction, globulin increase, gamma globulin or IgG increase, time extension of protrombin time, capability of positive reaction in self antibody and rheumatoid factors, capability of circulating immune complex increase, capability of addiments C3 and C4 reduction and the like, and has accurate remarkable clinical treatment effect and rapid effect taking.

The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and / or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The invention provides an indirect competitive quantum dot fluorescence immunological detection method for synchronously detecting multiple small molecular compounds and detection kit, wherein the immunological detection method is a liquid phase immunological detection method which uses an encoded microsphere as a solid phase carrier and a quantum dot as a fluorescent marker and is used for competitive specificity reactions of a small molecular compound antigen. c Firstly, a captured antigen is covalently bound to the surface of the encoded microsphere, an indirect competitive fluorescent immune complex of microsphere-captured antigen-detected antibody-second antibody-quantum dot is formed in a filter film plate reaction hole through capturing the antigen, detecting the antibody and binding the second antibody specificity, and then the indirect competitive fluorescent immune complex flows across a suspension chip or a detection region of a flow analysis system one by one under the restraint of the sheath fluid, recognizes different encoded microspheres and detects the fluorescent intensity (or average fluorescence intensity) of the quantum dot to complete the detection. A plurality of small molecule compounds in the same sample can be synchronously detected, and one or more small molecule compounds in different samples can also be detected. The invention has the advantages of fast speed and high flux.

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.

A process for preparing a patient-specific immunoadsorber, which comprises (i) extracting a body fluid from a patient having an immunopathological condition, the fluid containing immune complexes that are relevant to that immunopathological condition, (ii) contacting the extracted fluid with an adsorbent for the immune complexes to form adsorbed immune complexes, (iii) eluting the adsorbed complexes to form an eluate, (iv) fractionating the eluate into a plurality of immune complex component fractions, and (v) immobilizing the immune complex components on one or more biologically compatible carriers activated to bond to its surface one or more desired immune complex components.

An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, an HCV adsorption apparatus including said adsorbent, and a adsorbing method for removing HCV are provided. An adsorbent for removing hepatitis C virus which comprises a compound capable of adsorbing hepatitis C virus as immobilized on a water-insoluble carrier, an adsorption apparatus including said adsorbent, and an adsorbing method for removing HCV.

The invention discloses an application of a Raman encoding microsphere and a method for detecting a tumor marker by utilizing the Raman encoding microsphere, wherein the application of the Raman encoding microsphere refers to the application of the Raman encoding microsphere in tumor marker detection. The method for detecting the tumor marker by utilizing the Raman encoding microsphere comprises the following steps: dispersing the Raman encoding microsphere into a phosphoric acid buffer solution and adding a detection antibody for reaction, thus obtaining a nano probe; then utilizing bovine serum albumin to seal a space bit on the surface of the nano probe, thus obtaining a nano prober marked by Raman encoding; adding serum containing a tumor marker into a solid-phase antibody, reacting and adding the nano prober marked by Raman encoding, thus obtaining an immune complex; and after enriching the immune complex through an additionally added magnetic field, performing SERS (surface enhanced Raman scattering) spectrum detection. The Raman encoding microsphere used in the invention has an ultra-strong SERS effect, and can be used for performing quantitative analysis on a polycomponent ultratrace object, and selecting a large number of molecules with different SERS characteristic oscillation as markers to detect various matters to be detected simultaneously.

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.

The present invention provides a human thyroglobulin antibody magnetic separation enzymatic chemiluminescent immunoassay method, belonging to the field of immunodetection and analysis technology. Said method includes the following steps: making antigen human thyroglobulin be connected with Fe3O4 mincrosphere surface as solid phase reagent, the diameter of Fe3O4 microsphere is 0.1-5.0 microns, after the self-body antibody human thyroglobulin antibody being in the sample is trapped and two antibodies are labeled by enzyme reagent, the solid phase-antigen-antibody-enzyme-labeled two-antibody sandwiched immune complex can be formed.

A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.

A blood purification sorbent for antibody removal belongs to the technical field of biomedicine, which consists of the two parts of solid-phase carrier material and a petunidin fixed on the carrier by chemical coupling. The molecular structure of the petunidin is shown as above, wherein, one atom among A, B and C is N, the others are C; n is 0-2. The blood purification sorbent can adsorb the antibody component in plasma and autoantibodies such as rheumatoid factor, antinuclear antibody, etc. in heavy load, has limited nonspecific adsorption to other plasma components such as seralbumin, etc., and also has low preparation cost and stable physicochemical property. The material can be used as adsorption filler of a blood purification device for removing the autoantibody and immune complex in the plasma.

The invention provides a synchronous and indirect competitive immunological detection method and a kit of plural small molecular compounds. The immunological detection method is a liquid phase immunological detection method which uses an encoded microsphere as a solid phase carrier and phycoerythrin as a fluorescent marker and is used for competitive specificity reactions of a small molecular compound antigen. Firstly, a captured antigen is covalently bound to the surface of the encoded microsphere, an indirect competitive fluorescent immune complex of microsphere-captured antigen-detected antibody-second antibody-phycoerythrin is formed in a filter film plate through capturing the antigen, detecting the antibody and binding the second antibody specificity, and then the indirect competitive fluorescent immune complex flows across a suspension chip or a detection region of a flow analysis system one by one, recognizes different encoded microspheres and detects the fluorescent intensity of the phycoerythrin to complete the detection. Different captured antigens are connected by using the different encoded microspheres, a plurality of small molecule antigens in the same sample can be synchronously detected, and one or more small molecule antigens to be detected in different samples can also be detected. The invention has the advantages of fast speed and high flux.

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, an HCV adsorption apparatus including said adsorbent, and a adsorbing method for removing HCV are provided.An adsorbent for removing hepatitis C virus which comprises a compound capable of adsorbing hepatitis C virus as immobilized on a water-insoluble carrier, an adsorption apparatus including said adsorbent, and an adsorbing method for removing HCV.

The invention discloses a gastrin-17 enzymatic chemiluminescence immunoassay kit and belongs to the technical field of chemiluminescence immunoassay analysis. The kit comprises an enzyme label liquid, a gastrin-17 standard, gastrin-17 monoclonal antibody-coated immunomagnetic beads, a sample diluent, a chemiluminescent substrate liquid and a washing liquid. The principle of the gastrin-17 enzymatic chemiluminescence immunoassay kit comprises that a gastrin-17 monoclonal antibody is connected to the surface of a magnetic bead so that a solid phase agent is obtained, and through capture of gastrin-17 in a sample and use of an enzyme-labeled anti-gastrin-17 monoclonal antibody, a solid phase-antibody-antigen-enzyme-labeled antibody sandwiched immune complex is formed. Through combination of a chemiluminescence technology and an immunomagnetic bead technology, the prepared kit has the advantages of high sensitivity, good specificity, wide linearity range and good stability and can satisfy clinical requirements on stomach function detection.

A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.

The present invention provides a FcγRIIa transgenic non-human animal model for autoimmune disease, particularly arthritis. This invention also provides a method of using this model to screen compounds that can reduce aberrant immune activity including aberrant immune complex formation aberrant immune complex clearance and immune complex induced inflammation. This invention also provides means of using this model to treat or prevent autoimmune disease.

The invention relates to a magnetic particle chemiluminescence immunoassay method for human thyroglobulin antibodies (TGAb) and belongs to the technical field of immunoassay. TG antigens marked by fluorescein isothiocyanate (FITC) and human IgG antibodies marked by alkaline phosphatase are combined to form an antigen-antibody-second enzyme-labeled antibody sandwich immune complex with a sandwich-like structure. Then, magnetic particles connected with FITC antibodies are added, the antigen-antibody complex is connected to the magnetic particles through specific combination of the FITC antibodies and the FITC and directly deposited in an external magnetic field, and the complex formed by immune reaction can be separated from the other non-combined substances without centrifuging. A kit combines chemiluminescence with the magnetic particles to provide a reaction system close to a homogeneous phase. Compared with the prior art, the kit has the advantages of higher sensitivity, wide linear range, quickness and the like; the cost of a product is greatly reduced; and the kit has a broad application prospect on the aspects of clinical examination and the like.

The invention relates to a dinucleotide-labelled ratio electrochemical immunosensor. The dinucleotide-labelled ratio electrochemical immunosensor is characterized in that DNA3 of sulfydryl and ferrocene are respectively labelled at the two assembled ends of the surface of a gold electrode and are hybridized with methylene-blue-labelled complementary DNA1-antibody1 so as to form a ratio electrochemical immunosensor interface. When target protein exists, a DNA2-antibody2, the target protein and the DNA1-antibody1 form sandwiched immune complex to generate a vicinal effect, and DNA2 is hybridized with DNA1, so that the DNA1-antibody1 is separated from a sensing interface, and freed DNA3 forms a hairpin structure on the surface. In the process, methylene blue and the ferrocene with electrochemical activity are separated from and close to the surface of the electrode respectively, and the oxidized electric currents of the methylene blue and the ferrocene are reduced and increased respectively. By detecting the ratio of the two currents, the concentration of the target protein in the solution is detected. The immunosensor is high in sensitivity, wide in the detection range, realizes fast and one-step detection of protein, and has clinical application value.

The invention provides an immunoassay based on a carbon nanomaterial (carbon spot), comprising the following steps of: step A, preparing a carbon spot, and marking an immunoreagent antigen or antibody on a surface of the carbon spot so that the carbon spot becomes an immunoreagent-marked carbon spot; step B, mixing the immunoreagent-marked carbon spot, a sample to be tested and a solid phase substance coated by the immunoreagent antigen or antibody to complete immunoreactions, thus forming an immune complex, and separating the immune complex from a free immunoreagent; and step C, adding an oxidant to the immune complex for chemiluminescence detection, and / or directly enabling the immune complex to be subjected to fluorescence detection. According the immunoassay based on the carbon nanomaterial, the chemiluminescence detection and the fluorescence detection can be performed by using the carbon nanomaterial, and the optical stability is good.